Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 30

Results For "company"

4867 News Found

Biocon Biologics honored as 2025 Asia IP Elite by IAM for 9th consecutive year
News | December 18, 2025

Biocon Biologics honored as 2025 Asia IP Elite by IAM for 9th consecutive year

This recognition demonstrate excellence in intellectual property (IP) value creation.


Godavari Biorefineries launches US biotech arm to advance novel cancer therapies
News | December 18, 2025

Godavari Biorefineries launches US biotech arm to advance novel cancer therapies

The move strengthens GBL’s clinical-stage presence in the United States


Remedium Lifecare is now Supha Pharmachem
News | December 17, 2025

Remedium Lifecare is now Supha Pharmachem

The company shall process the change of name application with BSE Ltd. in due course


Gujarat Kidney and Super Speciality to file IPO at Rs.108- Rs.114 per share
News | December 17, 2025

Gujarat Kidney and Super Speciality to file IPO at Rs.108- Rs.114 per share

The company operates a chain of mid-sized multi-speciality hospitals


Eli Lilly re-elects Nobel Laureate Carolyn Bertozzi to Board
People | December 17, 2025

Eli Lilly re-elects Nobel Laureate Carolyn Bertozzi to Board

Bertozzi currently serves as the Baker Family Director of Sarafan ChEM-H, Anne T. and Robert M. Bass Professor at Stanford University, and Investigator of the Howard Hughes Medical Institute


Bristol Myers Squibb launches AI-powered ‘Mosaic’ hub in Mumbai
News | December 17, 2025

Bristol Myers Squibb launches AI-powered ‘Mosaic’ hub in Mumbai

India plays a critical role in Bristol Myers Squibb’s global strategy


Merck KGaA launches ChemiSphere App to digitize lab workflows
Digitisation | December 17, 2025

Merck KGaA launches ChemiSphere App to digitize lab workflows

The ChemiSphere app exemplifies how M-Trust technology transforms workflows into seamless digital experiences


Pfizer cuts 2026 revenue outlook amid COVID-19 & patent losses
News | December 17, 2025

Pfizer cuts 2026 revenue outlook amid COVID-19 & patent losses

The pharmaceutical giant now expects 2026 revenues to land between $59.5 billion and $62.5 billion